Suppression of psychedelic research and use

Suppression of psychedelic research and use was not a single event but a sequence of institutional and legal pressures that narrowed what counted as legitimate science, acceptable treatment, and permissible drug use. The conflict centered on a difficult boundary: psychedelic therapy was presented both as a possible clinical intervention and as an experience with spiritual and cultural consequences. Efforts to contain those consequences helped drive sanctioned work into the underground, even as later clinical findings reopened the question of what medicine could accommodate.

A challenge to psychiatric boundaries

The emerging psychedelic model unsettled psychiatry partly because it proposed a different scale and purpose for treatment. Earlier psychotomimetic theories described drug effects as resembling familiar psychoses, while psycholytic practice could be assimilated as an adjunct to psychoanalysis. Psychedelic therapy was harder to fit: instead of a succession of weekly sessions, it could center on one high-dose session intended to produce a conversion experience. That proposal challenged established expectations about treatment and the respective roles of patient and therapist.

The approach also brought spiritual language and practice into a medical setting. Charles Grob later characterized this crossing of religion and science, sickness and health, and healer and sufferer as applied mysticism. Its emphasis on set and setting made the treatment appear close to shamanic practice, a resemblance that could trouble psychiatrists seeking secure scientific standing. In this dispute, the issue was not simply whether a drug had an effect. The therapy asked whether the surrounding context, a guide’s role, and the meaning of an experience belonged inside or outside the clinical account.

The professional climate hardened during the early 1960s. By 1963, influential psychiatric voices were criticizing researchers who had taken the drugs themselves, arguing that personal experience compromised their competence and objectivity. Criticism in medical journals associated investigators’ experiences with bias and described an aura of magic around the drugs. Such objections fed a wider concern that psychedelic research blurred the line between scientific inquiry and mystical enthusiasm.

Scientific standards and institutional resistance

The rise of the double-blind, placebo-controlled trial as the gold standard for drug evaluation added a methodological obstacle. Psychedelic effects could make it apparent to participants, and sometimes to guides, whether psilocybin or a placebo had been administered. Researchers also faced the problem of separating the chemical’s effects from the influence of expectations, the treatment setting, and the therapists present. These factors were not incidental details easily removed from the experiment; they were among the conditions through which psychedelic therapy was understood to work.

A further difficulty was that the treatment seemed to depend on an experience, sometimes described as spiritual, rather than on a strictly pharmacological effect alone. The clinical model therefore resisted the usual effort to isolate one variable and measure it independently. This methodological friction could serve as more than a technical challenge: it helped define which kinds of therapeutic claims were legible to mainstream medicine and which appeared too entangled with religion, suggestion, or personal meaning to qualify as reliable science.

Al Hubbard’s work exposed that boundary in another way. In 1955, he established the Commission for the Study of Creative Imagination, recruiting researchers and other figures while naming himself its scientific director. Its practical reach may have been limited, but its existence signaled an effort to take psychedelic inquiry beyond medicine’s focus on illness. Sidney Cohen resigned from its board in 1957. Hubbard himself increasingly questioned science as an end in itself and sought something beyond empirical manipulation. The dispute was thus also about the purpose of research: treating illness, investigating experience, or changing culture.

Prohibition and the underground

The expanding cultural ambitions surrounding psychedelics sharpened the conflict. The book contrasts the first generation’s search for a workable container—medical, scientific, or religious—with the later view associated with Timothy Leary and the counterculture that no such container was necessary and that people could proceed on their own. That contrast gave the argument about use immediate stakes. A guided and bounded therapeutic practice was not equivalent to widespread, unguided experimentation, but public controversy made the distinction harder to sustain.

In 1970, the federal government placed psychedelics in Schedule I (United States), prohibiting their use for any purpose. Sanctioned psychedelic therapy ended, and practitioners faced a choice between stopping and continuing outside official permission. Leo Zeff chose to continue underground. He had found that psychedelics could help patients move past defenses, bring unconscious material forward, and reach spiritual insights, sometimes in a single session. The reported promise of the work did not remove its legal risk; it was the reason he accepted that risk.

Zeff’s underground practice also illustrates how suppression changed the form of therapy rather than simply erasing it. Guides developed protocols that included strict confidentiality, a prohibition on sexual contact, and obedience to the therapist’s instructions during a session. Ceremonial elements, such as taking the medicine from a cup, gave the act a marked place in the treatment. These procedures attempted to provide a stable social container for powerful experiences at a time when formal clinical practice was unavailable. The underground was therefore both a consequence of prohibition and a setting in which practitioners preserved and codified methods that could not openly be used.

A contested return to legitimacy

Later research revived the clinical question without dissolving the older dispute. Trials at New York University and Johns Hopkins University examined psilocybin for people with cancer, while other studies considered depression and addiction. In December 2016, the two cancer studies were reported together. About 80 percent of participants showed clinically significant reductions in anxiety and depression, and the effects lasted at least six months. The intensity of the reported mystical experience closely correlated with the degree of symptom improvement in both trials.

Those results drew substantial interest, but the studies included only eighty subjects in total and required replication on a larger scale before rescheduling and treatment approval could be considered. The cautious return to respectability was visible in institutional responses: medical schools sought to participate in future trials, funders came forward, and New York University moved its treatment room from the dental college toward its main hospital and cancer center. Research that had been forced out of sanctioned practice was again attracting institutional support, though on conditions set by contemporary standards.

Renewed legitimacy did not settle what legitimate use should mean. Bob Jesse worried that making medicalization the sole path would confine psychedelics to the patient and the clinic. Rick Doblin looked toward broader legalization, while Jesse and Katherine MacLean favored more controlled forms of wider access. Jesse imagined trained guides working in multigenerational contexts; another proposal was a supportive setting for people seeking an experience for health, spiritual inquiry, or curiosity. Across these disagreements, the recurring question was whether safe and meaningful use required a durable social framework—or whether medical authorization alone could provide one. Suppression narrowed the available answers, but it did not end the argument over who could guide psychedelic experience, for what purpose, and under whose authority.